2021 Q4 Form 10-Q Financial Statement
#000095017021004376 Filed on November 12, 2021
Income Statement
Concept | 2021 Q4 | 2021 Q3 | 2021 Q1 |
---|
Balance Sheet
Concept | 2021 Q4 | 2021 Q3 | 2021 Q1 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $464.2M | $512.7M | $550.7M |
YoY Change | -26.67% | 39.77% | 286.73% |
Cash & Equivalents | $77.42M | $87.25M | $97.83M |
Short-Term Investments | $386.8M | $425.4M | $452.9M |
Other Short-Term Assets | $9.108M | $7.672M | $8.100M |
YoY Change | 586.36% | 16.24% | 145.45% |
Inventory | |||
Prepaid Expenses | $6.065M | ||
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $486.4M | $534.9M | $573.9M |
YoY Change | -25.68% | 28.68% | 224.97% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $13.93M | $14.74M | $1.420M |
YoY Change | 816.25% | 781.64% | -35.45% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | $26.05M | $19.09M | $53.00M |
YoY Change | 108.38% | 8.45% | |
Other Assets | $12.61M | $12.94M | $15.00M |
YoY Change | 1.14% | 3.78% | 11.11% |
Total Long-Term Assets | $74.66M | $67.34M | $76.30M |
YoY Change | 181.48% | 112.19% | 382.91% |
TOTAL ASSETS | |||
Total Short-Term Assets | $486.4M | $534.9M | $573.9M |
Total Long-Term Assets | $74.66M | $67.34M | $76.30M |
Total Assets | $561.1M | $602.2M | $650.2M |
YoY Change | -17.61% | 34.61% | 237.94% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $4.145M | $4.595M | $2.900M |
YoY Change | -3.49% | 23.62% | 45.0% |
Accrued Expenses | $25.75M | $23.45M | $26.71M |
YoY Change | -5.0% | -11.49% | 39.09% |
Deferred Revenue | $0.00 | ||
YoY Change | -100.0% | ||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $35.09M | $32.63M | $28.60M |
YoY Change | 10.69% | 6.42% | 30.59% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | $27.62M | $26.76M | $5.200M |
YoY Change | 2661.7% | 2332.73% | 205.88% |
Total Long-Term Liabilities | $27.62M | $26.76M | $5.200M |
YoY Change | 2661.7% | 2332.73% | 205.88% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $35.09M | $32.63M | $28.60M |
Total Long-Term Liabilities | $27.62M | $26.76M | $5.200M |
Total Liabilities | $62.71M | $59.39M | $33.80M |
YoY Change | 91.6% | 86.81% | 43.22% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$230.4M | -$180.2M | |
YoY Change | 301.28% | 525.39% | |
Common Stock | $728.7M | $723.1M | |
YoY Change | 3.27% | 62.7% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $498.4M | $542.8M | $616.5M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $561.1M | $602.2M | $650.2M |
YoY Change | -17.61% | 34.61% | 237.94% |
Cashflow Statement
Concept | 2021 Q4 | 2021 Q3 | 2021 Q1 |
---|
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001538927 | ||
CY2021Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
2011-12-31 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
CY2021Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2021-09-30 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2021 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity File Number
EntityFileNumber
|
001-39333 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
Forma Therapeutics Holdings, Inc. | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
37-1657129 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
300 North Beacon Street | ||
dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 501 | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Watertown | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MA | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
02472 | ||
dei |
City Area Code
CityAreaCode
|
617 | ||
dei |
Local Phone Number
LocalPhoneNumber
|
679-1970 | ||
dei |
Security12b Title
Security12bTitle
|
Common stock, par value $0.001 per share | ||
dei |
Trading Symbol
TradingSymbol
|
FMTX | ||
dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | ||
dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
CY2021Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
47404601 | |
CY2021Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
87248000 | |
CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
282689000 | |
CY2021Q3 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
425433000 | |
CY2020Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
350365000 | |
CY2021Q3 | us-gaap |
Income Taxes Receivable
IncomeTaxesReceivable
|
14066000 | |
CY2020Q4 | us-gaap |
Income Taxes Receivable
IncomeTaxesReceivable
|
15273000 | |
CY2021Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
8139000 | |
CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
6120000 | |
CY2021Q3 | us-gaap |
Assets Current
AssetsCurrent
|
534886000 | |
CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
654447000 | |
CY2021Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
14741000 | |
CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1520000 | |
CY2021Q3 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
19088000 | |
CY2020Q4 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
12534000 | |
CY2021Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
20569000 | |
CY2021Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
12941000 | |
CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
12470000 | |
CY2021Q3 | us-gaap |
Assets
Assets
|
602225000 | |
CY2020Q4 | us-gaap |
Assets
Assets
|
680971000 | |
CY2021Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
4595000 | |
CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
4295000 | |
CY2021Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
23453000 | |
CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
27104000 | |
CY2021Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
4541000 | |
CY2021Q3 | us-gaap |
Taxes Payable Current
TaxesPayableCurrent
|
45000 | |
CY2020Q4 | us-gaap |
Taxes Payable Current
TaxesPayableCurrent
|
301000 | |
CY2021Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
32634000 | |
CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
31700000 | |
CY2021Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
26760000 | |
CY2020Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
1027000 | |
CY2021Q3 | us-gaap |
Liabilities
Liabilities
|
59394000 | |
CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
32727000 | |
CY2021Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2020Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2021Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | |
CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | |
CY2021Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
47399873 | |
CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
47300231 | |
CY2021Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
47378041 | |
CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
47248685 | |
CY2021Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
47000 | |
CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
47000 | |
CY2021Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2020Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2021Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
CY2021Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2020Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2021Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2020Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2021Q3 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
723033000 | |
CY2020Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
705607000 | |
CY2021Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-180249000 | |
CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-57410000 | |
CY2021Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
542831000 | |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
648244000 | |
CY2021Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
602225000 | |
CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
680971000 | |
CY2021Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
30684000 | |
CY2020Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
24780000 | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
88614000 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
68501000 | ||
CY2021Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
12749000 | |
CY2020Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
7460000 | |
us-gaap |
Operating Expenses
OperatingExpenses
|
123701000 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
35087000 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
22841000 | ||
us-gaap |
Restructuring Charges
RestructuringCharges
|
63000 | ||
CY2021Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
43433000 | |
CY2020Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
32240000 | |
us-gaap |
Operating Expenses
OperatingExpenses
|
91405000 | ||
CY2021Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-43433000 | |
CY2020Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-32240000 | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-123701000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-91405000 | ||
fmtx |
Gain On Hit Discovery Divestiture
GainOnHitDiscoveryDivestiture
|
23312000 | ||
CY2021Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
216000 | |
CY2020Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
870000 | |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
770000 | ||
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
2406000 | ||
CY2021Q3 | us-gaap |
Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
|
-70000 | |
CY2020Q3 | us-gaap |
Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
|
-52000 | |
us-gaap |
Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
|
215000 | ||
us-gaap |
Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
|
-2668000 | ||
CY2021Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
146000 | |
CY2020Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
818000 | |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
985000 | ||
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
23050000 | ||
CY2021Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-43287000 | |
CY2020Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-31422000 | |
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-122716000 | ||
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-68355000 | ||
CY2021Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
7000 | |
CY2020Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-3806000 | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
123000 | ||
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-26529000 | ||
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-43294000 | |
CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-27616000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-122839000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-41826000 | ||
fmtx |
Accretion Of Cumulative Dividends And Issuance Costs On Series Redeemable Convertible Preferred Stock Basic
AccretionOfCumulativeDividendsAndIssuanceCostsOnSeriesRedeemableConvertiblePreferredStockBasic
|
-3736000 | ||
CY2021Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-43294000 | |
CY2020Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-27616000 | |
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-122839000 | ||
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-45562000 | ||
CY2020Q3 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-8000 | |
CY2021Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-43294000 | |
CY2020Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-27624000 | |
us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-122839000 | ||
us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-45562000 | ||
CY2021Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.91 | |
CY2020Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.67 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-2.60 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-2.74 | ||
CY2021Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.91 | |
CY2020Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.67 | |
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-2.60 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-2.74 | ||
CY2021Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
47365704 | |
CY2020Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
41088261 | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
47333652 | ||
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
16616143 | ||
CY2021Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
47365704 | |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-43585000 | |
CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
579395000 | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
16616143 | ||
CY2020Q2 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
25587000 | |
CY2020Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
41088924 | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
47333652 | ||
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
18246000 | |
CY2020Q1 | fmtx |
Accretion Of Cumulative Dividends On Redeemable Convertible Preferred Stock
AccretionOfCumulativeDividendsOnRedeemableConvertiblePreferredStock
|
-1936000 | |
CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
3000 | |
CY2020Q1 | fmtx |
Stock Issued During Period Value Exercise Of Warrants To Purchase Common Stock
StockIssuedDuringPeriodValueExerciseOfWarrantsToPurchaseCommonStock
|
12000 | |
CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1210000 | |
CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
11230000 | |
CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
28765000 | |
CY2020Q2 | fmtx |
Accretion Of Cumulative Dividends On Redeemable Convertible Preferred Stock
AccretionOfCumulativeDividendsOnRedeemableConvertiblePreferredStock
|
-1800000 | |
CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1256000 | |
CY2020Q2 | fmtx |
Conversion Of Temporary Equity To Common Stock Value
ConversionOfTemporaryEquityToCommonStockValue
|
141867000 | |
CY2020Q2 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
25587000 | |
CY2020Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
293707000 | |
CY2020Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
142000 | |
CY2020Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-25440000 | |
CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
438497000 | |
CY2020Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2129000 | |
CY2020Q3 | fmtx |
Change In Estimate Of Initial Public Offering Costs
ChangeInEstimateOfInitialPublicOfferingCosts
|
-369000 | |
CY2020Q3 | fmtx |
Stock Issued During Period Value Exercise Of Warrants To Purchase Common Stock
StockIssuedDuringPeriodValueExerciseOfWarrantsToPurchaseCommonStock
|
2961000 | |
CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-27616000 | |
CY2020Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
415602000 | |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
648244000 | |
CY2021Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
333000 | |
CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3848000 | |
CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-35960000 | |
CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
616465000 | |
CY2021Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
92000 | |
CY2021Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
6423000 | |
CY2021Q3 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
29000 | |
CY2021Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
6701000 | |
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-43294000 | |
CY2021Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
542831000 | |
us-gaap |
Profit Loss
ProfitLoss
|
-122839000 | ||
us-gaap |
Profit Loss
ProfitLoss
|
-41826000 | ||
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
672000 | ||
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1076000 | ||
fmtx |
Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
|
813000 | ||
fmtx |
Gain Loss On Lease Modification
GainLossOnLeaseModification
|
287000 | ||
us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
16972000 | ||
us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
4595000 | ||
us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
2597000 | ||
us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
-1024000 | ||
us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
-192000 | ||
fmtx |
Gain On Hit Discovery Divestiture
GainOnHitDiscoveryDivestiture
|
23312000 | ||
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-121000 | ||
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-89000 | ||
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-227000 | ||
us-gaap |
Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
|
-1207000 | ||
us-gaap |
Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
|
26555000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
2348000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
5432000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
272000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
355000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-3029000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
6280000 | ||
us-gaap |
Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
|
-256000 | ||
us-gaap |
Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
|
451000 | ||
fmtx |
Increase Decrease In Deferred Rent Noncurrent
IncreaseDecreaseInDeferredRentNoncurrent
|
-298000 | ||
fmtx |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-907000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-108585000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-83099000 | ||
us-gaap |
Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
|
514121000 | ||
us-gaap |
Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
|
343320000 | ||
us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
431475000 | ||
us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
38647000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
3721000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
134000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-86367000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-301967000 | ||
us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
293707000 | ||
us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
12000 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
454000 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
145000 | ||
fmtx |
Payment Of Public Offering Costs
PaymentOfPublicOfferingCosts
|
-943000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-489000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
293605000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-195441000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-91461000 | ||
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
285159000 | |
CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
173796000 | |
CY2021Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
89718000 | |
CY2020Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
82335000 | |
us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
7478000 | ||
fmtx |
Operating Lease Right Of Use Asset Obtained
OperatingLeaseRightOfUseAssetObtained
|
19312000 | ||
fmtx |
Accretion Of Preferred Return And Cumulative Dividends On Preferred Securities
AccretionOfPreferredReturnAndCumulativeDividendsOnPreferredSecurities
|
3736000 | ||
fmtx |
Public Offering Costs Included In Accounts Payable And Accrued Expenses
PublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
|
28000 | ||
fmtx |
Public Offering Costs Included In Accounts Payable And Accrued Expenses
PublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
|
369000 | ||
fmtx |
Net Exercise Of Warrants To Purchase Common Stock
NetExerciseOfWarrantsToPurchaseCommonStock
|
2961000 | ||
us-gaap |
Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
|
277000 | ||
fmtx |
Installment Receivable In Prepaid Expenses And Other Current Assets
InstallmentReceivableInPrepaidExpensesAndOtherCurrentAssets
|
14131000 | ||
fmtx |
Equity Consideration In Other Assets
EquityConsiderationInOtherAssets
|
10000000 | ||
us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
3000 | ||
fmtx |
Conversion Of Redeemable Convertible And Convertible Preferred Stock In To Common Stocks
ConversionOfRedeemableConvertibleAndConvertiblePreferredStockInToCommonStocks
|
142252000 | ||
CY2020Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2020Q2 | us-gaap |
Capital Units Authorized
CapitalUnitsAuthorized
|
160000000 | |
CY2020Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
CY2020Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2020Q4 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
45.25 | |
CY2020Q4 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
795000 | |
CY2020Q4 | fmtx |
Gross Proceeds From Follow On Public Offering
GrossProceedsFromFollowOnPublicOffering
|
275800000 | |
CY2020Q4 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
258600000 | |
CY2021Q3 | fmtx |
Aggregate Amount Of Issuance And Offering Cost
AggregateAmountOfIssuanceAndOfferingCost
|
200000000.0 | |
CY2021Q3 | fmtx |
Sales Agent Cash Commissions
SalesAgentCashCommissions
|
0.030 | |
CY2021Q3 | fmtx |
Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
|
531800000 | |
fmtx |
Short Term Highly Liquid Investments With Original Maturities
ShortTermHighlyLiquidInvestmentsWithOriginalMaturities
|
90 days or less | ||
CY2021Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
87248000 | |
CY2020Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
79865000 | |
CY2021Q3 | us-gaap |
Restricted Cash
RestrictedCash
|
2470000 | |
CY2020Q3 | us-gaap |
Restricted Cash
RestrictedCash
|
2470000 | |
CY2021Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
89718000 | |
CY2020Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
82335000 | |
CY2021Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
8900000 | |
CY2021Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
7500000 | |
CY2021Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
7478000 | |
CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
27104000 | |
CY2021Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
26705000 | |
CY2021Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
3025000 | |
CY2020Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
1027000 | |
CY2021Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
5879000 | |
CY2021Q3 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
529374000 | |
CY2020Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
625392000 | |
CY2020Q4 | us-gaap |
Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
|
362912000 | |
CY2021Q3 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
|
92700000 | |
CY2020Q4 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
|
93700000 | |
CY2020Q4 | fmtx |
Manufacturing And Clinical Prepaid Expenses
ManufacturingAndClinicalPrepaidExpenses
|
3068000 | |
CY2020Q3 | fmtx |
Accretion Of Cumulative Dividends Redeemable Convertible Preferred Shares
AccretionOfCumulativeDividendsRedeemableConvertiblePreferredShares
|
46.37 | |
CY2021Q3 | us-gaap |
Held To Maturity Securities
HeldToMaturitySecurities
|
444521000 | |
CY2021Q3 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
|
59000 | |
CY2021Q3 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
|
20000 | |
CY2021Q3 | us-gaap |
Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
|
444560000 | |
CY2020Q4 | us-gaap |
Held To Maturity Securities
HeldToMaturitySecurities
|
362899000 | |
CY2020Q4 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
|
38000 | |
CY2020Q4 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
|
25000 | |
CY2021Q3 | fmtx |
Manufacturing And Clinical Prepaid Expenses
ManufacturingAndClinicalPrepaidExpenses
|
3187000 | |
CY2021Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
22427000 | |
CY2020Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
13065000 | |
CY2021Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
7686000 | |
CY2020Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
11545000 | |
CY2021Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
14741000 | |
CY2021Q3 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
4485000 | |
CY2020Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
1725000 | |
CY2021Q3 | us-gaap |
Other Receivables
OtherReceivables
|
467000 | |
CY2020Q4 | us-gaap |
Other Receivables
OtherReceivables
|
1327000 | |
CY2021Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
8139000 | |
CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
6120000 | |
CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1520000 | |
CY2021Q3 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
300000 | |
CY2020Q3 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
300000 | |
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
700000 | ||
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
1100000 | ||
CY2021Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
312000 | |
us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1112000 | ||
CY2021Q3 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
255000 | |
us-gaap |
Variable Lease Cost
VariableLeaseCost
|
738000 | ||
CY2021Q3 | us-gaap |
Lease Cost
LeaseCost
|
567000 | |
us-gaap |
Lease Cost
LeaseCost
|
1850000 | ||
CY2021Q3 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
220000 | |
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1258000 | ||
CY2020Q4 | fmtx |
Accrued Expenses And Other Liabilities Current Net
AccruedExpensesAndOtherLiabilitiesCurrentNet
|
27104000 | |
CY2020Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
6834000 | |
CY2021Q3 | fmtx |
Other Research And Development Related Accruals
OtherResearchAndDevelopmentRelatedAccruals
|
1567000 | |
CY2020Q4 | fmtx |
Other Research And Development Related Accruals
OtherResearchAndDevelopmentRelatedAccruals
|
338000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
1110000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
4843000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
4986000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
4222000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
4349000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
27645000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
47155000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
15854000 | |
CY2021Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
31301000 | |
fmtx |
Operating Lease Weighted Average Incremental Borrowing Rate Percent
OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent
|
0.087 | ||
CY2021Q3 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P9Y6M | |
CY2021Q3 | fmtx |
Manufacturing And Clinical Accruals
ManufacturingAndClinicalAccruals
|
12922000 | |
CY2020Q4 | fmtx |
Manufacturing And Clinical Accruals
ManufacturingAndClinicalAccruals
|
17952000 | |
CY2021Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
6898000 | |
CY2021Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
967000 | |
CY2020Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1008000 | |
CY2021Q3 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
1099000 | |
CY2020Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
972000 | |
CY2021Q3 | fmtx |
Accrued Expenses And Other Liabilities Current Net
AccruedExpensesAndOtherLiabilitiesCurrentNet
|
23453000 | |
CY2021Q3 | fmtx |
Cost For Guarantees And Indemnities
CostForGuaranteesAndIndemnities
|
0 | |
CY2020Q4 | fmtx |
Cost For Guarantees And Indemnities
CostForGuaranteesAndIndemnities
|
0 | |
CY2019Q1 | us-gaap |
Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
|
0.40 | |
CY2019Q1 | us-gaap |
Restructuring Charges
RestructuringCharges
|
5400000 | |
us-gaap |
Restructuring And Related Activities Description
RestructuringAndRelatedActivitiesDescription
|
There were no restructuring activities during the nine months ended September 30, 2021 | ||
CY2019Q4 | us-gaap |
Restructuring Reserve
RestructuringReserve
|
325000 | |
us-gaap |
Restructuring Charges
RestructuringCharges
|
63000 | ||
us-gaap |
Severance Costs1
SeveranceCosts1
|
-388000 | ||
CY2020Q2 | us-gaap |
Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
|
20349223 | |
CY2021Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2021Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2020Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
CY2021Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2021Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2021Q3 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
10183274 | |
CY2021Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
6701000 | |
CY2020Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2129000 | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
16972000 | ||
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4595000 | ||
CY2021Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
6701000 | |
CY2020Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2129000 | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
16972000 | ||
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4595000 | ||
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4941537 | |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
8.62 | |
CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P9Y1M6D | |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
130802000 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1363220 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
34.92 | ||
us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
91560 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
5.14 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
51931 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
8.73 | ||
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
6161266 | |
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
14.49 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P8Y6M | ||
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
72281000 | |
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
2173996 | |
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
8.08 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P8Y1M6D | ||
CY2021Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
33742000 | |
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0098 | |
CY2020Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0036 | |
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
6161266 | |
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
14.49 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y6M | ||
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
72281000 | |
fmtx |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price1
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice1
|
34.92 | ||
fmtx |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price1
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice1
|
10.13 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0096 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0109 | ||
CY2021Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y1M6D | |
CY2020Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y10M24D | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | ||
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.775 | |
CY2020Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.761 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.779 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.748 | ||
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.000 | |
CY2020Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.000 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.000 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.000 | ||
CY2021Q3 | fmtx |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price1
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice1
|
23.38 | |
CY2020Q3 | fmtx |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price1
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice1
|
40.82 | |
CY2020Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
41088261 | |
CY2020Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
41088924 | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
100000 | ||
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-26500000 | ||
us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
29600000 | ||
us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
16600000 | ||
CY2019Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
1239000 | |
fmtx |
Contract With Customer Liability Current Deductions
ContractWithCustomerLiabilityCurrentDeductions
|
-1239000 | ||
us-gaap |
Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
|
0 | ||
us-gaap |
Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
|
0 | ||
CY2021Q3 | us-gaap |
Contract With Customer Asset Net
ContractWithCustomerAssetNet
|
0 | |
CY2020Q3 | us-gaap |
Contract With Customer Asset Net
ContractWithCustomerAssetNet
|
0 | |
us-gaap |
Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
|
17500000 | ||
CY2021Q3 | fmtx |
Prepaid Of Reimbursement Expense
PrepaidOfReimbursementExpense
|
500000 | |
CY2021Q3 | fmtx |
Equity Consideration
EquityConsideration
|
10000000.0 | |
CY2021Q3 | fmtx |
Cash Due At Closing
CashDueAtClosing
|
2961000 | |
CY2021Q3 | fmtx |
Installment Receivable
InstallmentReceivable
|
12593000 | |
CY2021Q3 | fmtx |
Equity Consideration
EquityConsideration
|
10000000 | |
CY2021Q3 | fmtx |
Fair Value Of Consideration
FairValueOfConsideration
|
25554000 | |
CY2021Q3 | us-gaap |
Disposal Group Including Discontinued Operation Accounts Payable
DisposalGroupIncludingDiscontinuedOperationAccountsPayable
|
159000 | |
CY2021Q3 | us-gaap |
Disposal Group Including Discontinued Operation Deferred Revenue
DisposalGroupIncludingDiscontinuedOperationDeferredRevenue
|
1239000 | |
CY2021Q3 | us-gaap |
Liabilities Of Disposal Group Including Discontinued Operation
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
|
1398000 | |
CY2021Q3 | us-gaap |
Disposal Group Deferred Gain On Disposal
DisposalGroupDeferredGainOnDisposal
|
2242000 | |
fmtx |
Impairment To Equity Consideration
ImpairmentToEquityConsideration
|
0 | ||
CY2020 | fmtx |
Impairment To Equity Consideration
ImpairmentToEquityConsideration
|
0 | |
CY2021Q3 | us-gaap |
Disposal Group Including Discontinued Operation Prepaid And Other Assets Current
DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
|
1117000 | |
CY2021Q3 | us-gaap |
Disposal Group Including Discontinued Operation Property Plant And Equipment Noncurrent
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
|
2398000 | |
CY2021Q3 | us-gaap |
Disposal Group Including Discontinued Operation Other Noncurrent Assets
DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets
|
125000 | |
CY2021Q3 | us-gaap |
Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
|
3640000 |